

Special Issue

Personalized Medicine in Autoimmune Diseases

Message from the Guest Editor

The ultimate aim of genomic studies in autoimmunity, and in any human disease, is to understand their pathogenesis in order to identify novel therapeutic approaches. The implementation of -omics techniques will bring considerable progress to our knowledge of disease etiology and manifestations and have a determinant impact on the discovery of new biomarkers suitable for clinical practice. Genomics is the key component in biomedical research toward personalized medicine. This Special Issue of the *Journal of Personalized Medicine* aims to highlight the current state of the utilization or implementation of genomic technologies in autoimmunity. Mainly, we call for papers that are focused on the field of genomics in autoimmune diseases, and their potential to be useful for the diagnosis and treatment of these conditions. We encourage the submission of reviews and original articles which describe a personalized medicine approach to the diagnosis, classification, and treatment approach to autoimmune diseases.

Guest Editor

Dr. Roberto Díaz Peña

Fundación Pública Galega de Medicina Xenómica, SERGAS, Grupo de Medicina Xenómica-USC, Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Spain

Deadline for manuscript submissions

closed (5 August 2021)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/54183

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).